Sanofi-Aventis
Sanofi-aventis
Pipeline, Products,Performance,Potential
| Publication Date | September 2007 |
| Publisher | Espicom |
| Product Type | Report |
| Pages | 212 |
| ISBN Number | not applicable |
| Product Code | ESP00909 |
Price
approximately: $381 | €277
Order above formats by FAX
Summary
Sanofi-Aventis Was Formed In August 2004, When Sanofi-Synthlabo Acquired Control Of Aventis. Subsequently, On 31st December 2004, Aventis Merged With And Into Sanofi-Aventis, With Sanofi-Aventis As The Surviving Company. The Combined Entity Ranks Third Amongst Research-Based Pharmaceutical Companies Behind Pfizer And Glaxosmithkline.
Sanofi-Aventis Is Focused On Two Core Areas, Pharmaceuticals (Principally Prescription Drugs) And Human Vaccines. Within The Pharmaceutical Area, Sanofi-Aventis Is Active In The Following Therapeutic Areas: Cardiovascular/Thrombosis, Metabolism, Oncology, Central Nervous System And Internal Medicine (Which Includes Respiratory/Allergy, Urology, Arthritis/Osteoporosis And Anti-Infectives).
The Company Has A Strong Position In Europe, Particularly The Key Markets Of Germany, France And Italy. In Addition, The Acquisition Of A Shareholding In Zentiva In March 2006, Reaffirms Sanofi-Aventis' Commitment To Emerging Eastern European Markets. The Acquisition Of Aventis In August 2004, Also Significantly Strengthened Sanofi-Synthlabo's Position In The Us. Aventis Also Brought With It A Significant Presence In Latin America.
Continued Growth Of Key Products Such As Taxotere Are Currently Stimulating Growth For Sanofi-Aventis In Japan; The Approval Of Plavix For The Treatment Of Stroke (January 2006) Will Further Boost Sales And Is Expected To Expand Sanofi-Aventis' Profile Within This Market. In Addition, In July 2007, Sanofi-Aventis Announced The Buy Back In Japan Of Marketing Rights From 1st January 2008, Of Seven Of Its Products. These Products Are Currently Marketed By Chugai And Mitsubishi. This Marks A New Strategy For Sanofi-Aventis In Japan.
Of Sanofi-Aventis' Top 15 Products, Six Recorded Strong Double-Digit Growth In 2006, Three Moderate Single-Digit Growth And One Maintained Fairly Static Sales. Five Products Showed A Decline In Sales; Allegra And Amaryl In Particular, Were Hit Particularly Hard By Intense Generic Competition, Falling By 48.9 And 33.4 Per Cent Respectively.
Pharmaceutical Company Intelligence Reports From Espicom Provide A Full Review Of The Company's Activities Together With Five-Year Sales Forecasts For Its Key Products. The Company's Financial Performance Is Covered In-Depth, From Its Latest Results To A Complete Analysis Of Its Latest Full Fiscal Year And An Outlook For The Future. A Section On Company Strategy Covers Mergers, Acquisitions And Divestitures, Key Agreements, Products And R&D. An Overview Of Key Products And R&D Is Followed By A Comprehensive Review Of The Company's Product Portfolio And Research And Development Pipeline By Therapeutic Area. In Addition, Supplementary Appendices Provide More In-Depth Information On Financials, Agreements And Corporate Events.
Contents
- Executive Summary
- Introduction
- Financial Performance 2006
- Sales and Market Position
- Income
- Expenditure
- Capital Expenditure
- R&D Expenditure
- Divisional Performance
- Geographic Performance
- Company Strategy
- Research & Development Strategy
- Mergers, Acquisitions and Divestitures
- Mergers
- Acquisitions
- Divestitures
- Key Agreements
- Production
- Employees
- Product Performance Forecasts
- Key Products
- Discontinued Products
- Pipeline Analysis
- Discontinued R&D Projects
- Conclusions
- Therapeuti C Area Fo Cus
- R&D PIPELINE
- Cardiovas Cular / Thrombosis
- Marketed Products
- Cardiovascular
- Aviator/Aprovel/Avapro/Avalide/CoAprovel
- Delix/Tritace/Triatec
- Thrombosis
- Lovenox/Clexane
- Plavix/Iscover
- R&D Projects
- Cardiovascular
- Ataciguat (HMR1766)
- AVE0657
- AVE1231
- AVE3085
- AVE9488
- Celivarone
- HMR1069
- Ilepatril
- Multaq
- SL 65.0472
- XRP0038 (NV1FGF)
- Thrombosis
- AVE3247
- Biotinylated idraparinux
- Idraparinux
- Octaparine
- Otamixaban
- SR 123781
- SR 128428
- SR 128429
- Growth Forecast
- ON COLOGY
- Marketed Products
- Eloxatin
- Fasturtec/Elitek
- Taxotere
- R&D Projects
- Alvocidib
- Aflibercept
- AVE1642
- AVE8062
- AVE9633
- Larotaxel
- S-1
- SSR 244738
- SSR97225
- TroVax
- Uvidem
- Xaliproden
- XRP6258
- Growth Forecast
- Marketed Products
- Acomplia/Zimulti
- Copaxone
- Depakine
- Stilnox/Stilnoct/Ambien/Myslee
- Others
- R&D Projects
- Amibegron
- AVE1625
- AVE1701
- AVE8112
- AVE9897
- Dianicline
- Eplivanserin
- Nerispirdine
- Saredutant
- SSR 125543/SSR 126374
- SSR 149415
- SSR 180575
- SSR 180711
- SSR 241586
- SSR 411298
- Surinabant
- Teriflunomide
- Volinanserin
- Growth Forecast
- META BOLIS M / DIA BETES
- Marketed Products
- Apidra
- Amaryl
- Lantus
- R&D Projects
- AVE0010 (ZP10)
- AVE0847
- AVE0897
- AVE2268
- AVE5530
- AVE8134
- SAR7226
- Growth Forecast
- VA CCINES
- Marketed Products
- Diphtheria/Tetanus/Pertussis/Polio/HIB
- Adult Booster
- Gardasil
- Meningitis
- Travel Vaccines
- Zostavax
- R&D Projects
- Influenza Vaccines
- Cell-based influenza vaccine
- Flu Micro-Injection
- Flu Pandemia
- H7N1 vaccine
- HR51
- Other Vaccines
- Cytomegalovirus
- Dengue Fever Vaccine
- HIV/AIDS Vaccines
- Japanese Encephalitis Vaccine
- Melanoma Vaccine
- Pneumo
- Growth Forecast
- RES PIRATO RY / ALLERGY
- Marketed Products
- Allegra/
- Alvesco
- Nasacort/Nasacort AQ/Nasacort HFA
- R&D Projects
- AVE0675
- Arthritis / Osteo Porosis
- Marketed Products
- Actonel
- R&D Projects
- AVE1701
- AVE9897
- SAR479746
- Genito -Urina Ry
- Marketed Products
- Xatral
- R&D Projects
- ANTI -INFE CTIVE
- Marketed Products
- Ketek
- R&D Projects
- Ferroquine
- Picovir
- SAR97276
- XRP2868
- OT HER
- Marketed Products
- Flisint
- Sculptra
- R&D Projects
- Satavaptan
- SSR 150106
- SSR 240612
- Appen Dix 1 - Finan Cia L Perfo Rman Ce
- Full Year Results 2006
- Appen Dix 2 - Key Corporate Events
- Appen Dix 3 - Key Agree Ments
- aaiPharma
- Acambis plc
- Ajinomoto Co Inc
- Altana Pharma AG
- Amgen
- Astellas Pharma Inc
- Astex Technology
- AstraZeneca
- Becton Dickinson and Company (BD)
- Bristol-Myers Squibb
- Celera Genomics/Axys Pharmaceuticals
- Chinese Academy of Medical Science
- Chiron Corporation
- Coley Pharmaceutical Group Inc
- Crucell NV
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Debiopharm SA
- Eli Lilly
- Emergent BioSolutions
- French Ministry of Health
- GlaxoSmithKline
- IDM Pharma Inc
- ImmunoGen Inc
- Innogenetics NV/Institut National de la Sante et
- de la Recherche Medicale (INSERM)
- King Pharmaceuticals Inc
- LibraGen
- MedImmune Inc
- Millennium Pharmaceuticals Inc
- Nabi Biopharmaceuticals
- Novo Nordisk
- Oxford BioMedica plc (OBM)
- Pediatric Dengue Vaccine Initiative
- Pfizer
- Prasco Laboratories
- Procter & Gamble
- QLT Inc
- Regeneron Pharmaceuticals Inc
- Roche/Genentech
- SAS Institute
- Shionogi
- Taiho Pharmaceutical Co Ltd
- Teva Pharmaceutical Industries Ltd
- US Government
- VaxGen Inc
- Vermillion Inc
- Zealand Pharmaceuticals A/S
- Licensing
- Co-Promotion/Co-Marketing
- Appen Dix 4 - Inf Rast Ructure
- Research And Development Facilities
- Manufacturing Facilities
- Appen Dix 5 - Key Pharmaceuti Cal
- Subsi Dia Ries / Joint Vent Ures
- Subsidiaries
- Joint Ventures
- Appen Dix 6 - Product In Dex
- Index of Tables
- Principal Operating Results
- Operating Income By Business Area
- Operating Income By Geographical Area
- Capital Expenditure By Geographic Area
- R&D Expenditure By Business Area
- Sales By Business Area
- Total Human Vaccine Sales
- Total Net Sales By Geographic Area
- Total Assets By Geographic Area
- Consolidated Employees By Geographic Area
- Consolidated Employees By Main Category Of Function
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Cardiovascular / Thrombosis Products, 2006
- Sales of Aprovel/Avapro/Karvea by Geographical Area
- Sales of Plavix/Isocover by Geographical Area
- Major Oncology Products, 2006
- Major Central Nervous System Products, 2006
- Major Metabolism / Diabetes Products, 2006
- Vaccine Sales by Area
- Major Respiratory / Allergy Products, 2006
- Major Arthritis / Osteoporosis Products, 2006
- Major Genito-urinary Products, 2006
- Major Fully-Consolidated Subsidiaries
- Index of Charts
- Sales, Costs and Operating Income, 2006
- Capital Expenditure By Geographic Area, 2006
- R&D Expenditure By Business Area, 2006
- Sales By Business Area, 2006
- Breakdown of Vaccine Sales, 2006
- Total Net Sales By Geographic Area
- Total Assets By Geographic Area, 2006
- Employees By Geographic Area, 2006
- Consolidated Employees By Function, 2006
- Sales of Top 15 Products (2001A-2011E)
- Top Selling Products, 2006
- Breakdown of Product Sales, 2006
- Aprovel sales (2001A-2011E)
- Delix sales (2001A-2011E)
- Lovenox Sales (2001A-2011E)
- Plavix sales (2001A-2011E)
- Multaq Sales (2009E-2015E)
- XRP0038 Sales (2011E-2015E)
- Biotinylated Idraparinux Sales (2010E-2015E)
- Octaparine Sales (2011E-2015E)
- Eloxatin sales (2001A-2011E)
- Taxotere sales (2001A-2011E)
- Aflibercept Sales (2011E-2015E)
- Larotaxel Sales (2010E-2015E)
- S-1 Sales (2009E-2015E)
- TroVax Sales (2010E-2015E)
- Acomplia Sales (2006A-2012E)
- Copaxone Sales (2001A-2011E)
- Depakine Sales (2001A-2011E)
- Stilnox Sales (2001A-2011E)
- Eplivanserin Sales (2009E-2015E)
- Saredutant Sales (2009E-2015E)
- Amaryl Sales (2001A-2011E)
- Lantus sales (2001A-2011E)
- Vaccine Sales, 2006
- Allegra Sales (2001A-2011E)
- Nasacort Sales (2001A-2011E)
- Actonel Sales (2001A-2011E)
- Xatral Sales (2001A-2011E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
